Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of California, San Diego

Division of University of California
www.ucsd.edu

Latest From University of California, San Diego

What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib

Medicxi-funded Impact Biomedicines gave Sanofi a stake in the start-up to acquire fedratinib and bring the JAK2 inhibitor, which was placed on a clinical hold in 2013, to patients who are out of options.

Financing Business Strategies

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.

Deals Platform Technologies

Precision Medicine In Psychiatry: Astellas Joins Search For Biomarkers, Drug Targets

Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.

Research and Development Strategies Clinical Trials

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

ImmunoOncology Cancer
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register